Hypothesis

Endothelial mitochondrial DNA (mtDNA) release acts as an early danger signal that reprograms circulating monocytes into senescent, SASP‑producing immune cells, thereby turning the immune system into a driver of vascular aging.

Mechanistic Rationale

Aged endothelial cells exhibit eNOS uncoupling and reduced BH₄, leading to oxidative stress that damages mitochondria and promotes mtDNA efflux into the bloodstream https://experts.illinois.edu/en/publications/endothelial-dysfunction-due-to-enos-uncoupling-molecular-mechanis/. Extracellular mtDNA engages Toll‑like receptor 9 (TLR9) on monocytes, triggering MyD88‑dependent NF‑κB activation and a concomitant drop in intracellular NAD⁺ via CD38 upregulation https://pubmed.ncbi.nlm.nih.gov/27235855/. This combination drives a stable p16^INK4a^‑positive senescent state and amplifies the SASP, including IL‑6, TNF‑α and ROS, which further impair endothelial eNOS coupling and increase ICAM‑1/VCAM‑1 expression https://pmc.ncbi.nlm.nih.gov/articles/PMC10026597/. Thus, endothelial mtDNA creates a feedforward loop where endothelial dysfunction begets immune senescence, which in turn worsens endothelial function—a reversal of the canonical view that immune failure is merely secondary.

Testable Predictions

1. In older humans, plasma mtDNA levels will positively correlate with monocyte senescence markers (p16^INK4a^, SASP cytokines) independent of chronological age.
2. Endothelial‑specific reduction of mtDNA release (e.g., via transgenic overexpression of mitochondrial transcription factor A, TFAM, or the ubiquitin ligase MITOL) will lower monocyte senescence and improve vascular function in aged mice, even when systemic immune cells are untouched.
3. Pharmacologic blockade of TLR9 (e.g., with ODN‑2088) will prevent monocyte senescence induced by exogenous mtDNA and rescue endothelial function in aged mice, whereas NF‑κB inhibition alone will not fully suppress the SASP if mtDNA signaling persists.

Potential Experimental Approaches

• Isolate endothelial cells from young and old mice, measure mitochondrial ROS, mtDNA release (by qPCR for circulating mtDNA), and correlate with eNOS coupling status.
• Treat primary human monocytes with purified endothelial mtDNA; assess TLR9 phosphorylation, NAD⁺ levels, p16^INK4a^ expression, and SASP secretion.
• Generate Tie2‑Cre;TFAM overexpression mice; perform flow cytometry for monocyte p16^INK4a^, SASP profiling, and perform wire myography or Doppler ultrasound to assess arterial stiffness.
• Administer TLR9 antagonist to aged wild‑type mice and compare monocyte senescence and endothelial function to controls.

If these experiments confirm that endothelial mtDNA drives monocyte senescence, targeting the endothelial‑mitochondrial‑immune axis could break the vicious cycle and delay vascular aging before global immune rejuvenation is attempted.